In the NSCLC cohort of another meta-analysis carried out by Grassadonia et al., PFS was higher in immunotherapy-treated males than in females, and anti-CTLA-4 treatment was associated with longer OS in males [117]. Here, CTLA4 is linked to non-small cell lung carcinoma.